{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:21:06Z","timestamp":1770067266080,"version":"3.49.0"},"reference-count":6,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Infectious Diseases"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/s1473-3099(17)30752-1","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T18:49:19Z","timestamp":1513882159000},"page":"245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Dengvaxia: age as surrogate for serostatus"],"prefix":"10.1016","volume":"18","author":[{"given":"Ma\u00edra","family":"Aguiar","sequence":"first","affiliation":[]},{"given":"Nico","family":"Stollenwerk","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1473-3099(17)30752-1_bib2","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1473-3099(16)30168-2","article-title":"The risks behind Dengvaxia recommendation","volume":"16","author":"Aguiar","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/S1473-3099(17)30752-1_bib3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/14760584.2017.1276831","article-title":"Consider stopping Dengvaxia administration without immunological screening","volume":"16","author":"Aguiar","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/S1473-3099(17)30752-1_bib4","doi-asserted-by":"crossref","first-page":"e0005179","DOI":"10.1371\/journal.pntd.0005179","article-title":"The impact of the newly licensed dengue vaccine in endemic countries","volume":"10","author":"Aguiar","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/S1473-3099(17)30752-1_bib5","article-title":"Dengvaxia efficacy dependency on serostatus: a closer look at more recent data","author":"Aguiar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S1473-3099(17)30752-1_bib6","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1016\/j.vaccine.2017.06.004","article-title":"ADE and dengue vaccination","volume":"35","author":"Mart\u00ednez-Vega","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/S1473-3099(17)30752-1_bib9","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1126\/science.aaf9590","article-title":"Benefits and risks of the Sanofi-Pasteur dengue vaccine: modeling optimal deployment","volume":"353","author":"Ferguson","year":"2016","journal-title":"Science"}],"container-title":["The Lancet Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473309917307521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473309917307521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T09:24:22Z","timestamp":1761470662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473309917307521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1473309917307521"],"URL":"https:\/\/doi.org\/10.1016\/s1473-3099(17)30752-1","relation":{},"ISSN":["1473-3099"],"issn-type":[{"value":"1473-3099","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dengvaxia: age as surrogate for serostatus","name":"articletitle","label":"Article Title"},{"value":"The Lancet Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1473-3099(17)30752-1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}